Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Condition(s):Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Recurrent Uterine Corpus CarcinomaLast Updated:July 23, 2019Completed